Last reviewed · How we verify
Nicoderm C-Q Transdermal Product
Nicoderm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.
Nicoderm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation. Used for Smoking cessation aid for nicotine dependence.
At a glance
| Generic name | Nicoderm C-Q Transdermal Product |
|---|---|
| Also known as | NRT, NRT+ |
| Sponsor | University of Miami |
| Drug class | Nicotine replacement therapy (NRT) |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
The transdermal patch provides a steady, controlled release of nicotine through the skin into the bloodstream, bypassing the lungs and avoiding combustion byproducts. This maintains nicotine levels to suppress cravings and withdrawal symptoms while the user gradually reduces dependence. The patch is typically used as part of a comprehensive smoking cessation program.
Approved indications
- Smoking cessation aid for nicotine dependence
Common side effects
- Skin irritation at patch site
- Headache
- Nausea
- Dizziness
- Sleep disturbances
- Vivid dreams
Key clinical trials
- Feasibility of Delivering VergeRx at FQHCs (NA)
- Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia (NA)
- Mindfulness Based Smoking Cessation Among Cancer Survivors (PHASE4)
- Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study (NA)
- Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts (PHASE2, PHASE3)
- Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients (PHASE4)
- A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers (PHASE1)
- Cytisine Compared to Combination NRT in Relapsed Smokers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicoderm C-Q Transdermal Product CI brief — competitive landscape report
- Nicoderm C-Q Transdermal Product updates RSS · CI watch RSS
- University of Miami portfolio CI